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Abstract
 .Leukotriene B LTB is a potent lipid mediator of inflammation and is involved in the receptor-mediated activation of4 4
a number of leukocyte responses including degranulation, superoxide formation, and chemotaxis. In the present research,
 .stimulation of unprimed polymorphonuclear leukocytes neutrophils with LTB results in the transient release of4
arachidonate as measured by mass. This release of arachidonate was maximal at an LTB concentration of 50–75 nM and4
 .peaked at 45 s after stimulation with LTB . The transient nature of this release can be attributed, in part, to a fast -60 s4
metabolism of the added LTB . Moreover, the inhibition of the reacylation of the released arachidonate with thimerosal4
results in greater than 4-times as much arachidonate released. Thus, a rapid reacylation of the released arachidonate also
contributes to the transient nature of its measured release. Multiple additions of LTB , which would be expected to more4
closely resemble the situation in vivo where the cell may come into contact with an environment where LTB is in near4
w3 xconstant supply, yielded a more sustained release of arachidonate. No release of H arachidonate was observed when using
w3 xH arachidonate-labeled cells. This indicates that the release of arachidonate as measured by mass is most probably the
result of hydrolysis of arachidonate-containing phosphatidylethanolamine within the cell since the radiolabeled arachidonate
is almost exclusively incorporated into phosphatidylcholine and phosphatidylinositol pools under the non-equilibrium
 .radiolabeling conditions used. Consistent with the role of cytosolic phospholipase A cPLA in the release of2 2
arachidonate, potent inhibition of the LTB -stimulated release was observed with methylarachidonylfluorophosphonate, an4
 .inhibitor of cPLA IC of 1 mM . The bromoenol lactone of the calcium-independent phosphospholipase A . failed to2 50 2
affect LTB -stimulated release of arachidonate in these cells. q 1997 Elsevier Science B.V.4
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1. Introduction
The leukotrienes and prostaglandins are important
lipid mediators which are derived from arachidonic
 .acid. Polymorphonuclear leukocytes neutrophils
have been shown to synthesize and release arachi-
 .donate and leukotriene B LTB when treated with4 4
non-physiological stimuli such as the calcium
ionophore A23187 or with receptor-dependent ago-
w xnists such as the chemotactic peptide fMLP 1–4 .
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Treatment with A23187 generates substantial quanti-
ties of LTB and other lipoxygenase products while4
the receptor-dependent agonists such as fMLP, C5a,
 .and platelet activating factor PAF , which activate
other neutrophil functions, have been shown to pro-
duce only slight amounts of LTB and metabolites4
w x5 . However, the release of both arachidonate and its
metabolites with receptor-dependent agonist treat-
ment can be enhanced when the neutrophils are first
‘primed’ with agents such as granulocyte-macro-
phage colony-stimulating factor or tumor necrosis
 . w xfactor-a TNFa 3,6,7 .
Indeed, LTB itself has been shown to prime4
neutrophils for enhanced release of radiolabeled
arachidonate and LTB upon stimulation with4
w xionophore 8 . Additionally, LTB treatment of neu-4
trophils induces adherence to the endothelium,
chemotaxis, degranulation, and the generation of re-
w xactive oxygen metabolites 9–13 . These processes
result, ultimately, from the binding of LTB to a4
w xG-protein-coupled receptor 14 .
The enzyme responsible for the production of
arachidonate is phospholipase A . This enzyme cat-2
alyzes the hydrolysis of phospholipids which contain
an sn-2 arachidonoyl ester. Several different types of
phospholipases A have been identified; the best2
characterized are the 14 kDa secreted enzyme
 .  .sPLA , the 85 kDa cytosolic enzyme cPLA , and2 2
 .a calcium-independent enzyme CaI-PLA found in2
w xmyocardial tissue 15 .
cPLA is a calcium-dependent enzyme which, un-2
like the sPLA , has been shown to be selective for2
w xarachidonate-containing phospholipids 16,17 . The
cPLA is normally located in the cytosol, but translo-2
cates to the membrane in response to submicromolar
w xconcentrations of calcium 18,19 . Recent evidence
indicates that both phosphorylation of cPLA at ser-2
ine505, which may be catalyzed by MAP kinase
w x20,21 , and an increase in the cytosolic calcium
concentration are required to activate the enzyme to
w xproduce arachidonate 20–22 . Additionally, the en-
zyme shows a cooperative behavior with respect to
the molar fraction of arachidonate-containing phos-
pholipids. This may account for another mechanism
w xof regulation 23 .
The involvement of cPLA in the stimulated re-2
lease of arachidonate from neutrophils is evidenced
w xby work with permeabilized neutrophils 24 , and by
the observation that priming agents such as lipopoly-
saccharide and TNFa lead to a phosphorylation of
w xcPLA in neutrophils 25,26 .2
In this paper, we demonstrate that treatment of
neutrophils with LTB results in the release of4
arachidonate when measured by total mass, but not
w3 xby radiolabel in H arachidonate-labeled cells. This
release is shown to result from the action of cPLA 2
and is transient due to the quick metabolism of LTB4
as well as the re-esterification of released arachi-
donate. This is the first study to show that LTB4
alone can stimulate the mobilization of arachidonate.
The results also have important implications regard-
ing the function of neutrophils in environments in
vivo where the cell may be in contact with a more
continuous supply of leukotrienes.
2. Experimental
2.1. Materials
wThe radiolabeled arachidonic acid 5,6,8,9,11,12,
3  .x y1.13,15- H N , 100 Ci mmol was obtained from
DupontrNEN. MK-886 was purchased from Biomol,
 .methylarachidonylfluorophosphonate MAFP was
from Cayman Chemicals, and HELSS was from Cal-
 .biochem. HSA essentially fatty acid free was pur-
chased from Sigma.
2.2. Isolation of human neutrophils
Neutrophils were purified from whole blood
 .EDTA by dextran sedimentation and centrifugation
 .on ficoll-paque Pharmacia LKB for 15 min at 600
=g at 48C. Contaminating erythrocytes were re-
moved by hypotonic lysis. Neutrophils were resus-
pended at a working concentration of 5=106 cells
y1  .ml in Hank’s balanced salt solution HBSS con-
taining 0.2% HSA. Purity of the cell population
 .)95% was verified by Wrights stain and cell
viability was obtained by trypan blue exclusion )
.90% .
2.3. Measurement of released arachidonate from neu-
trophils
 6 y1.1 ml of neutrophils 5=10 cells ml were
preincubated for 5 min at 378C to equilibrate the
cells, and then stimulated with LTB or A23187.4
After various amounts of time, the reaction was
( )J.R. Burke et al.rBiochimica et Biophysica Acta 1359 1997 80–8882
terminated on ice by the addition of 1 ml of ice cold
HBSS. The samples were centrifuged at 600=g for
 .15 min at 48C. Heneicosanoic acid 21:0 was added
to the cells as an internal standard. The lipids were
then extracted by the procedure of Bligh and Dyer
w x27 . After drying under a stream of nitrogen, the
sample was resuspended in hexane. The free fatty
acids were isolated using silica SPE columns precon-
ditioned with hexane by eluting with 1:1 hexane:ether
mixture. After removing the solvent under a stream
of nitrogen, the fatty acids were derivatized to
pentafluorobenzyl esters by adding 30 ml of 30%
pentafluorobenzyl bromide in silylation grade aceto-
nitrile and 30 ml of diisopropylethylamine. The con-
tents were mixed well and incubated for 40 min at
408C. Solvents and excess reagents were evaporated
under a stream of nitrogen and the derivatives were
redissolved in 200 ml of gas chromatographic grade
hexane. Analysis of the fatty acids was performed on
a Hewlett Packard 5890 series II gas chromatograph
equipped with an electron capture detector, an
HP7673 autosampler, and a HP 486 Vectra data
processor. The PFB esters were separated on a fused
silica capillary column 30 m=0.25 mm id, DB-17,
.J&W Scientific . The injector temperature was 2508C
and the detector temperature was 2908C. The initial
column temperature was 408C for 1 min and in-
creased to 2208C at a rate of 208C miny1 and then to
2808C at a rate of 58C miny1. Helium was used as a
 y1.carrier gas 0.8 ml min and nitrogen was used as
the makeup gas. Samples in hexane were injected in
the splitless mode and the derivatized arachidonate
was quantitated using the heneicosanoic acid as an
internal standard.
For those experiments which measured the effect
of thimerosal, an inhibitor of fatty acid acylation
w x28,29 , cells were stimulated according to the proce-
dure above except that the cells were incubated for 5
min with 50 mM thimerosal prior to stimulation. For
those experiments which measured the effect of MK-
886 or HELSS, a 5 min preincubation with the agent
was used. A 20 min preincubation was used with
MAFP.
[3 ]2.4. H Arachidonate-labeling of neutrophils
 7 y1.Isolated neutrophils 4.4=10 ml were labeled
w3 xfor 15 min at 378C with 44 nM H arachidonate.
Cells were pelleted and washed with HBSS contain-
w3 xing 1% HSA to remove unincorporated H arachi-
donate. These cells were then repelleted and resus-
pended to a concentration of 5=106 cells mly1 as
described above. The analysis of the phosphoglycerol
w3 xpools into which the H arachidonate was incorpo-
rated was accomplished by extracting the lipids by
w xthe method of Bligh and Dyer 27 . Extracted lipids
were then separated into glycerolipid classes by TLC
using Silica Gel G plates developed in chloro-
 .formrmethanolracetic acidrwater 50:25:8:3, vrv .
Glycerolipids were visualized against standards by
exposure to iodine vapor or located using a ra-
diochromatogram imaging system Bioscan, Wash-
.ington, DC , and the amount of radioactivity was
determined by zonal scraping and liquid scintillation
counting.
w3 xThese H arachidonate-labeled neutrophils were
stimulated and quenched in the same manner as
described above. Cells were removed by centrifuga-
tion and the supernatants analyzed for the release of
label by liquid scintillation counting.
2.5. Leukotriene biosynthesis by neutrophils
To 1 ml of cells which had been stimulated and
quenched as described above was added 200 ml of
9% formic acid and PGB to a final concentration of2
250 ng mly1. After the eicosanoids were extracted
twice with 4 ml ethyl acetate, the combined organic
layers were evaporated under nitrogen and reconsti-
tuted in ethanol. Leukotrienes were then analyzed by
HPLC using an ultra-sphere ODS column 2.1 mm=
.250 mm, Rainin with spectroscopic detection at 280
nm. The mobile phase was 55:45 methanol:water pH
5.7 with phosphoric acid at a flow rate of 0.3 ml
miny1. After 5 min, the methanol was increased to
100% over 50 min. Spectrophotometric detection was
at 270 nm. The mass of LTB was quantitated by4
peak integration normalized by the internal standard
PGB .2
3. Results
3.1. Release of arachidonate from neutrophils treated
with LTB4
Treatment of neutrophils with LTB resulted in a4
transient production of arachidonate, as determined
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Fig. 1. LTB -stimulated release of arachidonate from neutrophils.4
Neutrophils were stimulated with 75 nM LTB either in the4
absence, closed circles, or presence, open circles, of HSA 2 mg
y1.ml . The mass of arachidonate produced was then determined
by gas chromatography as described in Section 2. The data
represent the average of measurements in duplicate from three
separate donors. The error is defined as the standard deviation.
by gas chromatography–electron capture to measure
 .the total mass, which peaked at 45 s see Fig. 1 . This
is in contrast to the release observed when stimulated
 .with the calcium ionophore A23187 Fig. 2 . The
A23187-induced release is not transient and peaks at
5 min. Both A23187 and LTB failed to stimulate the4
 .release of oleic or linoleic acids data not shown .
Arachidonate produced upon stimulation with LTB4
was not cell-associated but was released extracellu-
 .larly results not shown . The presence of HSA in-
creased the amounts of arachidonate by about 3-fold,
presumably by sequestering the arachidonate once
outside the cell.
As shown in Fig. 3, the release of arachidonate
was dependent on the concentration of LTB up to4
approximately 50 nM. Above this concentration, no
further increase in arachidonate production was ob-
served which is consistent with a saturation effect.
While 50 nM LTB is a substantially higher concen-4
tration than the value of 48–270 pM reported for the
w xdissociation constant of LTB from its receptor 30 ,4
the binding of LTB to the albumin present in the4
w xassay greatly reduces its effective concentration 31 .
Using neutrophils which had been radiolabeled
w3 xwith H arachidonate, TLC analysis of the phospho-
Fig. 2. A23187-stimulated release of arachidonate from neu-
trophils. Neutrophils were stimulated with 2.5 mM A23187 in the
 y1.presence of HSA 2 mg ml . The mass of arachidonate pro-
duced was then determined by gas chromatography as described
in Section 2. The data represent the average of measurements in
duplicate from three separate donors. The error bars represent the
standard deviation.
w3 xlipid classes showed most of the H arachidonate
was incorporated into phosphatidylcholine and phos-
phatidylinositol pools 23.3"1.5% and 30.8"1.9%,
Fig. 3. Concentration dependence of LTB -stimulated release of4
arachidonate. Neutrophils were stimulated with various concen-
 y1.trations of LTB in the presence of HSA 2 mg ml . The4
reactions were quenched 45 s after stimulation and the mass of
arachidonate produced was then determined as described in Sec-
tion 2. The data represent the average of measurements in
duplicate from three separate donors. The error bars represent the
standard deviation.
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.respectively with only 8.2 " 1.4% in phos-
phatidylethanolamine pools the remainder was in
. w3 xneutral lipids . Treatment of these H arachidonate-
labeled neutrophils with LTB failed to stimulate a4
w3 xmeasurable release of H arachidonate as shown in
Fig. 4. These radiolabeled neutrophils were able to
w3 xrelease sizable amounts of H arachidonate, how-
ever, when stimulated with the calcium ionophore
A23187.
3.2. Effect of a reacylation inhibitor on the release of
arachidonate induced by LTB4
While the presence of HSA would be expected to
aid in the sequestration of any hydrolyzed arachi-
donate once outside the cell, the transient production
of arachidonate shown in Fig. 1, demonstrates that
either the arachidonate is re-incorporated into cellular
phospholipid pools, or is metabolized by enzymes
such as cyclooxygenase or 5-lipoxygenase. In order
to address the possibility of reacylation, neutrophils
were treated with 50 mM thimerosal which blocks the
w xacylation of fatty acids 29 without inducing the
w3 xFig. 4. LTB - and A23187-stimulated release of H arachidonate4
w3 xfrom H arachidonate-labeled neutrophils. Neutrophils were
stimulated with either 75 nM LTB , open circles, or 2.5 mM4
A23187, closed circles. At the indicated times, samples were
quenched with equal volumes of ice-cold buffer and centrifuged.
w xThe released 3H arachidonate in the supernatant was quantitated
by scintillation counting. The data represent values from which
non-stimulated controls were subtracted and are the average of
three determinations from a single donor, although the same
trends were observed in three other experiments.
Fig. 5. Effect of thimerosal on LTB -stimulated release of arachi-4
donate. Neutrophils were stimulated with 75 nM LTB either in4
the absence, open circles, or presence, closed circles, of thimerosal
 .50 mM . The mass of arachidonate produced was then deter-
mined as described in Section 2. The data represent the average
of three determinations from a single blood donor, although the
same trends were observed in three other experiments.
w xrelease of arachidonate itself 28 . As shown in Fig.
5, treatment with thimerosal resulted in more than
4-times as much release of arachidonate. In contrast,
treatment with 10 mM MK886, an inhibitor of the
w x5-lipoxygenase activating protein inhibitor 32,33 ,
did not substantially affect the measured arachidonate
 .in LTB -stimulated neutrophils results not shown .4
Thus, metabolism toward 5-lipoxygenase products
 .was not considered to be significant vide infra .
3.3. Production and metabolism of LTB in LTB -4 4
stimulated neutrophils
Since it has been reported that treatment of neu-
trophils with LTB greatly enhances the ability of the4
cells to synthesize LTB from exogenously added4
w xarachidonate 34 , it was of interest to determine
whether treatment with LTB led to the further accu-4
mulation of LTB . Fig. 6 shows that while A231874
treatment resulted in the formation of large amounts
of LTB , LTB treatment alone did not lead to the4 4
formation of LTB above the levels added. In fact,4
the added LTB was completely metabolized in less4
than a minute as determined by the absence of the
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Fig. 6. LTB levels in neutrophils treated with A23187 or LTB .4 4
Neutrophils were stimulated with either 75 nM LTB , closed4
circles, or 2.5 mM A23187, open circles. At the indicated times,
samples were quenched and the LTB was measured as described4
in Section 2. The data represent the average of two determina-
tions from a single donor.
exogenously added LTB . The production of metabo-4
lites of LTB were not determined.4
To determine whether neutrophils encountering a
more constant concentration of LTB have the capac-4
ity to release more arachidonate, multiple additions of
LTB were made at 45 s intervals. As shown in Fig.4
7, this procedure indeed resulted in a more sustained
release of arachidonate. This release of arachidonate
is likely underestimated since the reacylation of
arachidonate represents the major route of metabolism
 .of the fatty acid see Fig. 5 .
3.4. Role of cPLA in the generation of arachidonate2
in LTB -stimulated neutrophils4
To determine which of the three phospholipases
A is responsible for the production of arachidonate2
in differentiated cells, pharmacological agents were
employed to determine effects on arachidonate re-
lease in the cells. The methylarachidonylfluorophos-
 .phonate MAFP is a potent inhibitor of cPLA 2
w xwhich does not inhibit the sPLA 35 . It has also2
been shown to inhibit the mobilization of arachi-
w xdonate in PAF-stimulated P388D 36 . Treatment of1
neutrophils with MAFP inhibited the release of
arachidonate with IC values of 1 and 0.4 mM when50
Fig. 7. Effect of multiple additions of LTB on arachidonate4
production in neutrophils. Neutrophils were stimulated with 75
 y1.nM LTB every 45 s in the presence of HSA 2 mg ml . The4
mass of arachidonate produced was then determined as described
in Section 2. The data represent the average of three determina-
tions from a single donor.
stimulated with LTB and A23187, respectively Fig.4
. w x8 . Since MAFP also inhibits the CaI–PLA 37 , it2
is unclear whether the cPLA or the CaI–PLA is2 2
Fig. 8. Inhibition of LTB - and A23187-stimulated arachidonate4
production by MAFP. Neutrophils were preincubated with the
indicated amount of MAFP for 20 min prior to a 45 s stimulation
with either 75 nM LTB , open circles, or 2.5 mM A23187, closed4
circles. The mass of arachidonate produced was then determined
as described in Section 2. The data represent the percent inhibi-
tion relative to a control without inhibitor and are the average of
three determinations from a single donor.
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responsible for the production of arachidonate in
these cells. To address this question, the cells were
 .treated with the bromoenol lactone HELSS inhibitor
of CaI–PLA . This compound is a mechanism-based2
inactivator of the CaI–PLA which does not inhibit2
w xsPLA or cPLA 38 , and has been shown to block2 2
enzyme activity in A-10 smooth muscle cells and
P388D cells at concentrations as low as 1–5 mM1
w x39,40 . Following HELSS treatment of neutrophils,
the arachidonate release induced by LTB was inhib-4
ited less than 10% at HELSS concentrations as high
 .as 100 mM results not shown . These results are
consistent with the involvement of cPLA , rather2
than sPLA or CaI–PLA , in the LTB -stimulated2 2 4
production of arachidonate in neutrophils. Indeed,
LTB has been shown to act through the LTB4 4
receptor to modulate cPLA and arachidonate release2
w x4 .
The role of cPLA in the production of arachi-2
donate is consistent with the observation that LTB4
treatment of neutrophils leads to the complete con-
version of the enzyme into the phosphorylated state
as determined by SDS–PAGE and immunoblot anal-
w xysis 4 . This is consistent with LTB acting through4
a receptor-mediated phosphorylation cascade. We
have determined that this phosphorylation occurred
 .by 45 s results not shown which demonstrates that
the time course of phosphorylation of cPLA corre-2
lates with the time required for maximal release of
arachidonate.
4. Discussion
In the present study, the unexpected finding that
LTB stimulates the release of arachidonate was4
observed. This release was not observed with cells
w3 xwhich had been radiolabeled with H arachidonate.
This, along with the fact that the release was tran-
sient, explains why other researchers measuring the
effect at 5 min of treatment with LTB on arachi-4
w xdonate release have not made this observation 4,41 .
It is interesting to note that the time course for
arachidonate production observed in the present re-
search correlates well with the 30–60 s required for
w xneutrophil aggregation stimulated by LTB 42 .4
Potent inhibition by MAFP, but not by HELSS, of
the release of arachidonate demonstrates that cPLA 2
is responsible for this release. That the release of
arachidonate is concomitant with the phosphorylation
of the cPLA induced by LTB supports the idea that2 4
phosphorylation of the enzyme is important in the
w xregulation of its function 15 .
The phospholipid source for this arachidonate re-
lease is most probably phosphatidylethanolamine
since two-thirds of the endogenous arachidonate in
neutrophils has been shown to be in this phospholipid
w xclass 43 . This is also consistent with the lack of
w3 xLTB -induced release of H arachidonate in neu-4
w3 xtrophils radiolabeled with H arachidonate since it
w3 xwas shown that the H arachidonate was mainly
localized into phosphatidylcholine and phosphatidyli-
nositol pools with very little associated with phos-
phatidylethanolamine in these non-equilibrium la-
beled cells. That phosphatidylethanolamine is the ma-
jor source of released arachidonate has also been
demonstrated in A23187-stimulated neutrophils and
w xmast cells 43–46 .
While stimulation of neutrophils with LTB leads4
to the release of arachidonate, it is not clear what
purpose this serves. It may be that the production of
arachidonate, which is then rapidly reacylated, is
simply an alternate form of phospholipid remodeling
usually thought to be catalyzed by acyltranferases.
This putative remodeling may then prime the cell for
optimal production of arachidonate and eicosanoids
when treated, either subsequently or simultaneously,
with some other agent. Indeed, LTB has been shown4
to prime neutrophils for enhanced release of arachi-
w xdonate when stimulated with fMLP 4 . Moreover,
priming of neutrophils with LTB leads to the in-4
creased synthesis of leukotrienes when stimulated
w xwith A23187 34,47 . A particularly intriguing idea is
that the LTB -stimulated release and reacylation re-4
ported here may represent a remodeling of arachi-
donate from phosphatidylethanolamine to phos-
phatidylcholine. Indeed, phosphatidylcholine has been
shown to be the source of arachidonate used for
w xleukotriene biosynthesis in neutrophils 44 and is the
phospholipid into which free arachidonate is incorpo-
 .rated vide supra .
Another important consideration is that the present
work uses isolated neutrophils. Therefore, the impor-
tant signaling between different cells in vivo has been
removed. Thus, while the arachidonate resulting from
the stimulation of neutrophils by LTB is shown not4
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to be used in producing additional leukotrienes, it
may be that this arachidonate is utilized by other cells
in vivo to produce eicosanoid products. This would
be similar to the example of hepatocyte biosynthesis
of LTB which requires LTA produced by a neigh-4 4
boring leukocyte, for instance, since hepatocytes lack
w xthe 5-lipoxygenase needed for LTA generation 48 .4
Moreover, the transient release of arachidonate
observed when stimulated with LTB also underesti-4
mates the importance of this process in vivo. As
shown in Fig. 7, if the neutrophils are treated with
multiple additions of LTB , a more sustained release4
of arachidonate is observed. This may more closely
resemble an environment in vivo where it can be
envisioned that neutrophils may be found in an in-
flamed tissue, for instance, where LTB is constantly4
produced from neighboring cells. This in vivo envi-
ronment, therefore, would be expected to yield a
more sustained and prolonged production of arachi-
donate from neutrophils.
In conclusion, the present research demonstrates
that treatment of neutrophils with LTB results in the4
production of arachidonate. The results also provide
mechanistic information on the role of leukotrienes in
the priming of neutrophil function. Moreover, these
findings have important ramifications on the role of
neutrophils in vivo where the cells may encounter
w xenvironments of constant leukotriene levels 49,50 .
References
w x1 P. Borgeat, B. Samuelson, Proc. Natl. Acad. Sci. USA 76
 .1979 2148–2155.
w x  .2 R.M.J. Palmer, J.A. Salmon, Immunology 50 1983 65–71.
w x  .3 M. Schatz-Munding, V. Ullrich, Eur. J. Biochem. 204 1992
705–712.
w x4 J. Wijkander, J.T. O’Flaherty, A.B. Nixon, R.L. Wykle, J.
 .Biol. Chem. 270 1995 26543–26549.
w x5 H. Salari, P. Braquet, P. Naccache, P. Borgeat, Inflamma-
 .tion 9 1985 127–135.
w x6 S.R. McColl, E. Krump, P.H. Naccache, P.E. Poubelle, P.
 .Braquet, M. Braquet, P. Borgeat, J. Immunol. 146 1991
1204–1211.
w x7 S.A. Bauldry, C.E. McCall, S.L. Cousart, D.A. Bass, J.
 .Immunol. 146 1991 1277–1285.
w x8 M.M. Billah, R.W. Bryant, M.I. Siegel, J. Biol. Chem. 260
 .1985 6899–6906.
w x9 W.E. Dahlen, J. Bjork, P. Hedquist, K.E. Arfors, S. Ham-
marstrom, J.A. Lindgren, B. Samuelsson, Proc. Natl. Acad.
 .Sci. USA 78 1981 3887–3891.
w x10 J. Palmblad, C.L. Malmsten, A.M. Uden, O. Radmark, L.
 .Engstedt, B. Samuelsson, Blood 58 1981 658–661.
w x11 C.M. Serhan, A. Radin, J.E. Smith, H. Korchak, B.
Samuelsson, G. Weissman, Biochem. Biophys. Res. Com-
 .mun. 107 1982 1006–1012.
w x12 R.L. Hoover, M.J. Karnovsky, K.F. Austen, E.J. Corey,
 .R.A. Lewis, Proc. Natl. Acad. Sci. USA 81 1984 2191–
2193.
w x  .13 R.J. Smith, S.S. Iden, B.J. Bowman, Inflammation 8 1984
365–384.
w x  .14 D.W. Goldman, E.J. Goetzl, J. Immunol. 129 1982 1600–
1604.
w x  .15 R.M. Kramer, in: M. Liscovitch Ed. , Signal-Activated
Phospholipases, R.G. Landes, Austin, TX, 1994, pp. 13–30.
w x16 E. Diez, P. Louis-Flamberg, R.H. Hall, R.J. Mayer, J. Biol.
 .Chem. 267 1992 18342–18348.
w x17 E. Diez, F.H. Chilton, G. Stroup, R.J. Mayer, J.D. Winkler,
 .A.N. Fonteh, Biochem. J. 301 1994 721–726.
w x  .18 J.Y. Channon, C.C. Leslie, J. Biol. Chem. 265 1990
5409–5413.
w x19 J.D. Clark, L.-L. Lin, R.W. Kriz, C.S. Ramesha, L.A.
 .Sultzman, A.Y. Lin, N. Milona, J.L. Knopf, Cell 65 1991
1043–1051.
w x20 L.-L. Lin, M. Wartmann, A.Y. Lin, J.L. Knopf, A. Seth,
 .R.J. Davis, Cell 72 1993 269–278.
w x21 A.R. Schievella, M.K. Regier, W.L. Smith, L.-L. Lin, J.
 .Biol. Chem. 270 1995 30749–30754.
w x22 R.M. Kramer, E.F. Roberts, J.V. Manetta, P.A. Hyslop, J.A.
 .Jakubowski, J. Biol. Chem. 268 1993 26796–26804.
w x23 J.R. Burke, M.R. Witmer, J. Tredup, R. Micanovic, K.
Gregor, J. Lahiri, K.M. Tramposch, J.J. Villafranca, Bio-
 .chemistry 34 1995 15165–15174.
w x24 S.A. Bauldry, R.E. Wooten, D.A. Bass, Biochim. Biophys.
 .Acta 1299 1996 223–234.
w x25 M.E. Doerfler, J. Weiss, J.D. Clark, P. Elsbach, J. Clin.
 .Invest. 93 1994 1583–1591.
w x26 W.H. Waterman, R.I. Sha’afi, Biochem. Biophys. Res.
 .Commun. 209 1995 271–278.
w x  .27 E.G. Bligh, W.J. Dyer, Can. J. Biochem. Physiol. 23 1959
190–196.
w x28 A. Hatzelmann, M. Haurand, V. Ullrich, Biochem. Pharma-
 .col. 39 1990 559–567.
w x29 M.L. Brown, C.A. Clark, R. Vaillancourt, D. Deykin,
 .Biochim. Biophys. Acta 1165 1992 239–247.
w x30 D.M. Slipetz, K.A. Scoggan, D.W. Nicholson, K.M. Met-
 .ters, Eur. J. Pharmacol. 244 1993 161–173.
w x31 S. Psychoyos, F.S. Usiel, M.M. Morrissey, V. Ganu, C.W.
 .Smith, J. Immunol. Methods 137 1991 37–46.
w x32 C.A. Rouzer, A.W. Ford-Hutchinson, H.E. Morton, J.W.
 .Gillard, J. Biol. Chem. 265 1990 1436–1442.
w x  .33 R.N. Young, Agents Actions Suppl. 34 1991 179–187.
w x34 P.P. McDonald, S.R. McColl, P.H. Naccache, P. Borgeat,
 .Br. J. Pharmacol. 107 1992 226–232.
( )J.R. Burke et al.rBiochimica et Biophysica Acta 1359 1997 80–8888
w x35 Z. Huang, P. Payette, K. Abdullah, W.A. Cromlish, B.P.
 .Kennedy, Biochemistry 35 1996 3712–3721.
w x  .36 J. Balsinde, E.A. Dennis, J. Biol. Chem. 271 1996 6758–
6765.
w x37 Y.-C. Lio, L.J. Reynolds, J. Balsinde, E.A. Dennis, Biochim.
 .Biophys. Acta 1302 1996 55–60.
w x38 S.L. Hazen, L.A. Zupan, R.H. Weiss, D.P. Getman, R.W.
 .Gross, J. Biol. Chem. 266 1991 7227–7232.
w x39 J.J. Lehman, K.A. Brown, S. Ramanadham, J. Turk, R.W.
 .Gross, J. Biol. Chem. 268 1993 20713–20716.
w x40 J. Balsinde, I.D. Bianco, E.J. Ackermann, K. Conde-Frie-
 .boes, E.A. Dennis, Proc. Natl. Acad. Sci. USA 92 1995
8527–8531.
w x41 S.M. Prescott, G.A. Zimmerman, G.A. Seeger, Biochem.
 .Biophys. Res. Commun. 122 1984 535–541.
w x  .42 Y.P. Rochon, M.M. Frojmovic, Blood 82 1993 3460–3468.
w x  .43 F.H. Chilton, T.R. Connell, J. Biol. Chem. 263 1988
5260–5265.
w x  .44 F.H. Chilton, Biochem. J. 258 1989 327–333.
w x45 T.G. Tessner, D.G. Greene, R.L. Wykle, J. Biol. Chem. 265
 .1990 21032–21038.
w x  .46 A.N. Fonteh, F.H. Chilton, J. Immunol. 148 1992 1784–
1791.
w x47 P.P. McDonald, S.R. McColl, P. Braquet, P. Borgeat, Br. J.
 .Pharmacol. 111 1994 852–860.
w x48 P.Y.-K. Wong, C.N. Serhan, Cell–Cell Interactions in the
Release of Inflammatory Mediators: Eicosanoids, Cytokines,
and Adhesion, Plenum, New York, 1991.
w x49 B. Zingarelli, F. Squadrito, P. Graziani, R. Camerini, A.P.
 .Caputi, Agents Actions 39 1993 150–156.
w x  .50 L. Michel, L. Dubertret, Arch. Dermatol. Res. 284 1992
S12–17.
